Press Releases
[Nov 2007] Innovative Drug Production Project secures funding from Technology Strategy Board
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, today announced that it has secured £350,000 in funding from the Technology Strategy Board. The award, one of the first since the Technology Strategy Board assumed responsibility for the government's collaborative research and development programme, will enable PolyTherics to work with Avecia Ltd, a leading contract development organization and manufacturer of biopharmaceuticals.
[Nov 2007] Imperial Innovations Annual Report - PolyTherics Limited
PolyTherics, a biotechnology company, has discovered a way of slashing the cost of the production of expensive drugs for life-threatening diseases, such as hepatitis C and cancer, by improving their performance in the body and therefore patients' prospects.
[Oct 2007] PolyTherics highlighted by UK Trade & Investment
PolyTherics has made a breakthrough that should soon start to bring huge benefits for sufferers of hepatitis C around the world. PolyTherics Ltd of London has discovered a way to deliver a new protein-based treatment that provides, at last, an affordable drug for people in developing countries where resources are limited and the disease most common.
[Aug 2007] PolyTherics and BioVectra dcl sign Manufacturing and Representation Deal
PolyTherics, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, today announced that it has signed a manufacturing and bilateral representation agreement with BioVectra dcl, a Canadian biopharmaceutical company that supplies specialty chemicals and contract manufacturing services to the pharmaceutical and biotechnology industry.
[Jun 2007] Innovative Biopharmaceutical Company, PolyTherics, raises over £2 million
Imperial Innovations Group plc, the technology commercialisation and investment company (AIM: IVO), Longbow Capital, which focuses on healthcare and technology investments and The Capital Fund, the £50 million Regional Venture Capital Fund for London, today announce that they have completed an investment round of £2.3 million in PolyTherics Limited ('PolyTherics'), an innovative biopharmaceutical company.
[Jan 2007] "PEG-ing makes cheaper drugs for developing countries"
UK and Indian scientists have embarked on a collaboration to develop a new protein-based treatment for hepatitis C, which they say will provide an affordable drug urgently needed in countries where resources are limited.
